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2nd Department of Intemal Medicine, Nagoya City University Medical School, Nagoya, Japan 
Angiotensin-converting enzyme (ACE) inactivates bradykinin, substance P and neurokinin A, which are believed to 
play important roles in the pathogenesis of asthma, especially in neurogenic inflammation. It has recently been 
shown that an insertion (1)ldeletion (D) polymorphism in the ACE gene accounts for variation in serum ACE levels. 
There are thus three genotypes (insertion homozygote, II; deletion homozygote, DD; heterozygotes, DI). The serum 
ACE level with the DD type is reported to be about double that of the II type and intermediate in the DI case. In 
the present study, we examined whether asthma is linked with this ACE gene polymorphism. 
Seventy-one patients with asthma (27 males and 44 females) and 142 sex- and age-matched healthy controls were 
determined for their genotype by the polymerase chain reaction (PCR) method. 
Twenty-five asthmatics demonstrated the II type (352%) 37 the DI type (52.1%), and nine the DD type (12.7%). 
There were no significant differences in the distributions of genotypes and serum ACE levels between healthy 
controls and patients. No significant differences were evident in serum IgE levels, age at onset, proportion of atopic 
type patients and severity of asthma among the three genotypes. 
We did not find any association between asthma and the ACE gene polymorphism in this study. 
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Introduction 
The angiotensin-converting enzyme (ACE) (kininase II, 
peptidyl-dipeptidase A; EC 3.4.15.1) inactivates bradykinin 
and tachykinins such as substance P (SP) and neurokinin A 
(NRA). These are considered to play important roles in the 
pathogenesis of asthma, especially in neurogenic inflam- 
mation. Bradykinin causes bronchoconstriction, enhances 
vascular permeability, leads to mucosal oedema, and 
increases the production of mucus by direct effects or 
stimulating release of neuropeptides, such as tachykinins 
from C-fibres (l-5). Patients with asthma are reported 
to show bronchial hyperreactivity to bradykinin, relative 
to healthy subjects (6). Tachykinins are inducers of airway 
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smooth muscle constriction, bronchial oedema, extra- 
vasation of plasma, and mucus hypersecretion, acting as 
important mediators of neurogenic inflammation (l-4,7). 
A number of investigators have reported that ACE inhibi- 
tors increase the bronchial responsiveness of patients with 
asthma (8,9). Furthermore, it is well known that they often 
cause non-productive coughing as a side-effect, possibly due 
to bradykinin influence on the airways. Thus changes in the 
enzyme may play a role in asthma pathogenesis. 
It has recently been shown that the ACE gene contains a 
polymorphism based on the presence [insertion (I)] or 
absence [deletion (D)] of a nonsense DNA fragment (10). 
The polymorphism is located in intron 16, so the ACE itself 
does not differ due to the genotypic variation, but the 
polymorphism accounts for 47% of the total phenotypic 
variance in serum ACE levels. There are three genotypes: 
deletion homozygotes, DD; insertion homozygotes, II; and 
heterozygotes, DI. The serum ACE level with the DD type 
is reported to be about double that of the II type and that 
of the DI type is intermediate. The DD genotype has been 
reported to be a genetic risk factor for myocardial infarc- 
tion, left ventricular hypertrophy (11,12), but the effects of 
ACE gene polymorphism in terms of susceptibility to 
development of asthma remain unclear (13). We therefore 
examined genes of asthmatic patients and controls to 
determine whether any association may exist. 
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TABLE 1. Subjects 
Sex Mean age 
Number 0-4 (year XL SE@ 
Asthmatic patients 71 44127 52.0 f 2.0 
Healthy controls 142 82154 51.9 l!z 1.2 
Materials and Methods 
SUBJECTS 
Seventy-one asthmatic patients living in central Japan were 
examined. All satisfied the American Thoracic Society 
criteria for asthma (14). We selected those subjects who had 
no cardiomegaly on chest radiography, normal findings on 
ECG, normal findings on UCG performed by cardiac 
specialists, FEV, >70% on spirogram, and normal findings 
on chest computed tomography (CT) evaluated by a radi- 
ologist, to exclude cardiogenic disease and pulmonary 
emphysema. Twenty-seven of the cases were males and 44 
were females. They had a mean age of 52.0 + 2.0 years 
(mean j, SEM). Forty-nine of the 71 patients had atopic, and 
22 non-atopic disease. According to the severity classifi- 
cation of the International Consensus Report on diagnosis 
and treatment of asthma, 25 cases were mild; 37 were 
moderate and nine were severe (15). 
As controls, 142 sex- and age-matched, unrelated healthy 
subjects from the same area of Japan were selected. They 
comprised 54 males and 88 females with a mean age of 
51.9 & 1.2 years. They did not have any past histories of 
pulmonary disease and atopic disease or any abnormalities 
on physical examination, chest radiography, spirograms, 
blood pressure testing, ECG, urinalysis and routine labora- 
tory blood testing. None was receiving medication at the 
time of evaluation. Informed consent was obtained from all 
the patients and healthy controls (Table 1). The percentages 
of current and past cigarette smokers in asthmatic patients 
were 14.8% (10/71) and 11.3% (8/71); and in healthy sub- 
jects were 21,8% (31/142) and 9.9% (14/142), respectively. 
DETERMINATION OF ACE GENOTYPES 
The D and I alleles were identified on the basis of poly- 
merase chain reaction (PCR) amplification of the respective 
fragments from intron 16 of the ACE gene and size 
fractionation and visualization by electrophoresis. DNA 
was extracted from peripheral leukocytes with standard 
techniques. PCR was performed with 20 pmol of each 
primer: sense oligo S’CTGGAGACCACTCCCATCCTT 
TCT3’ and anti-sense oligo: S’GATGTGGCCATCACATT 
CGTCAGAT3’ in a final volume of 25~1, containing 
1.5 KIM MgCl,, 50 mM KCl: 10 DIM Tris-HCl pH 8.3, 
0.2 mM of each dNTP, 1.25 unit of Taq polymerase (Perkin 
Elmer-Cetus, Norwalk, CT, U.S.A.). The DNA was ampli- 
fied for 30 cycles with denaturation at 94°C for 30 s, 
annealing at 58°C for 30 s, and extension at 72°C for 1 min, 
followed by final extension at 72°C for 5 min (DNA 
Thermal Cycler 480, Perkin Elmer-Cetus, Norwalk, CT, 
U.S.A.) (16,17). PCR products were electrophoresed in 2% 
agarose-gels with 5hg ethidium bromide per mm. The 
amplification products of the D and I alleles were identified 
by 300-nm UV trans-illumination as distinct bands (D 
allele: 191 bp; I allele: 478 bp) [Fig. l(a)]. 
As the D allele in heterozygous samples is preferentially 
amplified, each sample found to have the DD genotype was 
(b) 
FIG. 1. Determination of ACE genotypes. The left lane of each panel contains markers. (a) Shows part of a representative 
2% agarose gel stained with ethidium bromide and photographed under UV transillumination after PCR amplification 
with insertion-spanning primers. The upper band of 478 bp is the I allele and the lower band of 191 bp is the D allele 
(arrows). The II type is shown as a single upper band, the DD type as a single lower band, and the DI type as a double 
band. (b) Shows the results of screening for erroneous assignment of the DD genotype to DI samples with use of an 
insertion-specific primer. The sample in lane 1 is a standard for II and that in lane 2 is a standard for DI, followed by 
three samples (lanes 3-5) identified as DD with the insertion-spanning primer. A Dl sample previously misclassified as 
DD is present in lane 5. 
TABLE 2. Results of genotyping 
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II (%) DI (%) DD (“Yo) I allele/D allele 
Healthy controls 
n= 142 
Asthmatic patients 
n=71 
51 (40.1) 69 (48.6) 16 (11.3) 0.64410.356 
25 (35.2) 37 (52.1) 9 (12.7) 0.613/0.387 
No significant differences in the genotype distribution h2=0.497, d.f. =2, P=O.780) or the allele 
frequencies @=0.410, d.f.= 1, P=O.522) were noted between healthy controls and asthmatic 
patients. 
subjected to a second, independent PCR amplification with 
a primer pair that recognizes an insertion-specific sequence 
(hate 5a, S’TGGGACCACAGCGCCCGCCACTAC3’; 
hate 5c, 5’TCGCCAGCCCTCCCATGCCCATAA3’), 
with identical PCR conditions except for an annealing 
temperature of 67°C. The reaction yields a 335-bp amplicon 
only in the presence of an I allele, and no product in 
samples homozygous for DD (18,19). This procedure cor- 
rectly identified about 2% of samples (3/152) with the DI 
genotype that were misclassified as DD with the insertion- 
spanning primer [Fig. l(b)]. The PCR results were scored by 
two independent investigators, blind as to whether the 
sample was from an asthmatic patient or a control. 
SERUM IGE AND ACE LEVEL MEASUREMENT 
Serum ACE levels were measured by a calorimetric method 
(calorimetric assay kit, Fujizoki Assay, Tokyo, Japan) 
using p-hydroxyhippuryl-L-histidyl-L-leucine as the sub- 
strate (20). Serum IgE levels were measured by the 
radioimmunosorbent test (RIST). 
STATISTICAL ANALYSIS 
Values are expressed as means f SEM. The allele ratios and 
genotype distributions of asthmatic patients and healthy 
controls, and variation in clinical manifestation of the 
disease among the three genotypes were analysed with the 
chi-squared test. Analysis of serum ACE and IgE levels was 
performed using the Mann-Whitney U-test for comparison 
of the two groups, and the Kruskal-Wallis test for the three 
groups (21). A P-value ~0.05 was considered significant. 
Results 
GENOTYPE DISTRIBUTION 
Of the 142 healthy controls, 57 had the II genotype, 69 the 
DI type and 16 the DD type. The I allele/D allele (I/D) ratio 
was 0.64410.356. Of the 71 patients with asthma, 25 were 
type II, 37 were DI and nine were DD. The I/D ratio was 
0.61310.387. The observed genotype distributions were in 
agreement with the Hardy-Weinberg proportion. No sig- 
nificant differences in genotype distribution k2=0.497, 
d.f.=2, PzO.780) or the allele frequencies k2=0.410, 
d.f.=l, P=O.522) were observed between healthy subjects 
and asthmatic patients (Table 2). 
CLINICAL MANIFESTATION AND ACE GENE 
POLYMORPHISM 
No significant differences were found among the three 
genotypes regarding age at onset of asthma (P=O.957), for 
the proportion of patients with atopic and non-atopic type 
disease k2=0.164, d.f.=2, P=O.921) or for the severity of 
asthma @=5.70, d.f.=4, P=O.223) (Table 3). 
SERUM IGE AND ACE LEVELS 
In healthy controls, the average serum ACE levels of II, DI 
and DD individuals were 11.3 Jr 0.5, 13.7 f 0.5 and 
17.1 -f 0.8 IU l- I, respectively. For 70 of the 71 asthmatic 
patients, serum ACE levels were measured, the average 
values for the II, DI and DD types being 11.5 f 1.0, 
13.5 rt 06 and 14.5 f I.0 (IU 1 - ‘), respectively. Significant 
differences among the three genotypes were found for both 
asthmatic patients (PcO.05) and normal controls 
(P<O.OOOl). However, the serum ACE levels of asthmatic 
patients did not significantly differ from those of healthy 
controls in each genotype (Table 4). There were no signifi- 
cant differences in the serum IgE levels among the three 
genotypes in asthmatic patients (P=O.907). 
Discussion 
ACE is a widely distributed zinc-metalloproteinase, occur- 
ring, e.g., as a membrane-bound ectoenzyme on the surface 
of vascular endothelial cells and renal epithelial cells, and as 
a circulating enzyme in plasma. The ACE gene spans 21 k, 
is located on the 17th chromosome 923, and consists of 
26 exons and 25 introns. The polymorphism exists in 
intron 16. The length of the insertion is 287 bp, and it is a 
repetition of a meaningless Alu family configuration 
(22,23). It has not been resolved why the polymorphism 
influences the serum ACE level but some authors have 
suggested that the insertion/deletion may be in linkage 
disequilibrium with regulatory elements of the ACE gene, 
or that the insertion itself might modify the splicing process 
of the ACE precursor mRNA by interfering with the lariat 
formation step (10,24). 
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TABLE 3. Clinical manifestation of asthma and genotype 
Genotype 
II (%) 
n=25 
DI (%) DD (%) 
1il=36 n = 9 
Total 
n=71 
Age at onset of asthma (years) 37.8 I!= 4.2 376 zt 3.8 39.9 zt 6.9 38.0 zt 2.6 
Atopic 18 (72.0) 25 (67.6) 6 (66.7) 49 
Non-atopic 7 (28.0) 12 (32.4) 3 (33.4) 22 
Mild 12 (48.0) 10 (27.0) 1 (11.1) 23 
Moderate 11 (44.0) 21 (568) 7 (77.8) 39 
Severe 2 (8.0) 6 (16.2) 1 (11.1) 9 
All 71 asthmatic patients were evaluated for clinical manifestation. No significant difference in age 
at onset (P=O.957), frequencies of atopic type (%‘=0.164, d.f. =2, P=O,921) and severity of asthma 
k2=5.70, d.f. =4, P=O.223) were noted among the three genotypes. The severity was determined by 
the classification of the International Consensus Report on diagnosis and treatment of asthma. 
TABLE 4. Serum ACE and IgE levels 
Serum ACE level (1U I- ‘) 
Serum IgE level (IU ml - ‘) 
Healthy controls Asthmatic patients Asthmatic patients 
II 11.3 f 0.5 11.5 zt 1.0 522 + 195 
n=57 n=25 n=24 
DI 13.7 f 0.5 13.5 i 0.6 480 * 137 
n=69 n=36 n=36 
DD 17.1 i 0.8 14.5 i 1.0 294 f 109 
n=16 n=9 n=9 
Total 
P-value 
13.1 + 0.4 
iz= 142 
P<0~0001 
12.9 & 0.5 470 i 99 
n=70 n=69 
PCO.05 P=O.907 
The serum ACE level was measured for 70 of 71 asthmatic patients and for all 142 healthy controls. 
Significant differences were found among the three genotypes both for asthmatic patients and 
healthy controls, but not between these two groups. There were no significant differences in serum 
IgE level among the three genotypes 
Bradykinin and tachykinins are important mediators for 
neurogenic inflammation. Bradykinin is inactivated by 
ACE (kinase II) and kinase I (carboxypeptidase N), and 
tachykinins are mainly degraded by ACE and neutral 
endopeptidase (NEP; EC 3.4.24.11, enkephalinase) (l-5). 
Therefore, alteration in ACE may play a role in asthma. 
Non-productive coughing caused by ACE inhibitors is 
reported to be more frequent with the II genotype than in 
the other types (25). In addition, Morice et al. showed an 
increase in the sensitivity of the cough reflex to stimulation 
with distilled water in II genotype individuals (26). We 
therefore hypothesized that low ACE activity would 
predispose to development of asthma, and the II type may 
be a genetic risk factor for the disease due to the lower 
ability of inactivating bradykinin and tachykinins. In this 
study, however, we did not find any significant associ- 
ations between the ACE gene polymorphism and asthma. 
Moreover, the ACE genotype distribution of asthmatic 
patients did not significantly differ from that of 207 
sarcoidosis patients in our previous study k2=1.248, 
d.f.=2, P=O.536) (27). ,e 
To our knowledge: the influence of ACE gene poly- 
morphism on asthma has previously only been studied by 
Benessiano et al. (13). They examined 79 patients with 
asthma, 54 healthy subjects and 33 patients with non- 
asthmatic lung disease, and described a higher prevalence 
of the DD genotype in the first group. In contrast, we 
observed no significant difference in the genotype distribu- 
tions between asthmatic patients and healthy controls. This 
might be related to the fact that they examined fewer 
healthy subjects, and added patients with non-asthmatic 
lung disease to the control population. Second, a racial 
difference may exist. Some investigators have indicated 
that the I/D ratio depends upon race. In Caucasians, the 
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I/D ratio was reported to be 0.4110.59 by Rigat et al. (lo), 
0.4449/0.5551 by Lindpaintner et al. (19) and 0.43/0.57 
by Benessiano et al. (13), which means the D allele is 
dominant. However, in Japanese the I allele has been shown 
to be dominant by Furuya et al. (0.66/0.34) (25) and 
ourselves (0.654/0.346) (27). Third, the smaller difference 
in serum ACE levels among the three genotype in our 
asthmatic patients than that in healthy subjects might be of 
relevance. To our regret, since they did not describe serum 
ACE levels, we could not compare our data with their 
results. Finally, the fact that they did not correct for the 
mistyping that is said to occur for 45% of the DI type cases 
might also have affected their results (l&19,28). 
No significant differences between patients and healthy 
controls were found regarding serum ACE levels in the 
present study, but since measurement was during periods 
of stability, this might not be totally informative. In future, 
we will concentrate attention on levels during asthma 
attack. 
Although our results do not provide support for any 
association between the ACE gene polymorphism and 
asthma, they do not preclude a role for ACE in the 
pathogenesis of this disease. The potential association 
between ACE and asthma requires further investigation. 
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